Tuesday, October 4, 2022


Biotechnology News Magazine

MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that the first patient has been enrolled in the Company’s Phase 2 clinical trial of lead candidate MYMD-1, an oral immune regulator drug, as a therapy for delaying aging and expanding healthy lifespan.

The primary endpoint for the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of (TNF-α), tumor necrosis factor receptor I (TNFRI) and IL-6. TNF-α and IL-6 are the proteins in the body that cause inflammation and help activate the process of aging. The secondary measures of the trial will be the safety, tolerability, and pharmacokinetics in this population of patients.

“In a Phase 1 clinical trial of MYMD-1, we demonstrated the drug’s statistically significant efficacy in reducing levels of TNF-α, a key player in causing pathological aging, in the blood. The FDA has approved TNF-α reduction as the primary endpoint for our Phase 2 study, which we believe positions us well for a successful Phase 2 outcome,” said Chris Chapman, M.D., President, Director and Chief Medical Officer of MyMD. “The initiation of patient enrollment in this study advances our mission to slow the aging process, prevent loss of muscle tissue in aging, limit frailty, and extend healthy lifespan.”

MyMD Pharmaceuticals has stated that there are no FDA-approved drugs for treating aging disorders and extending healthy lifespan humans, a market expected to be at least $600 billion by 20251 according to a major investment bank. TNF-α blockers are the most prescribed drugs by revenue, a global market of approximately $40 billion per year,2 and, according to Nature Aging journal,3 a slowdown in aging that would increase life expectancy by one year is worth $38 trillion and by 10 years is worth $367 trillion.

In addition to aging, MYMD-1’s distinct action in regulating the immune system and treating chronic inflammation is being developed for the treatment of autoimmune disease, including rheumatoid arthritis (RA), multiple sclerosis (MS), diabetes, and inflammatory bowel disease.

“We intend to begin writing protocols for a Phase 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The rising prevalence of rheumatoid arthritis and other autoimmune and inflammatory diseases are driving demand for TNF inhibitors like MYMD-1, and we believe our orally administered drug with very low toxicity would be disruptive to the $60 billion market for RA if approved by the FDA for this indication.”

Rheumatoid arthritis affects approximately 40 million people worldwide.4

About MYMD-1

Originally developed for autoimmune diseases, MYMD-1’s primary purpose is to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan. Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. Its mechanism of action and efficacy in diseases including multiple sclerosis (MS) and thyroiditis have been studied through collaborations with several academic institutions. MYMD-1 is also showing promise in pre-clinical studies as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-proliferation therapeutic.

MYMD-1 has shown effectiveness in pre-clinical studies in regulating the immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-α), a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown in these pre-clinical studies to selectively block TNF-α when it becomes overactivated in autoimmune diseases and cytokine storms, but not block it from doing its normal job of being a first responder to any routine type of moderate infection. MYMD-1’s ease of oral dosing is another differentiator compared to currently available TNF-α blockers, all of which require delivery by injection or infusion. No approved TNF inhibitor has ever been dosed orally. In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation.


1 https://www.cnbc.com/2019/05/08/techs-next-big-disruption-could-be-delaying-death.html
2 October 9, 2019, Tumor Necrosis Factor (TNF) Inhibitor Drugs Market, Acumen Research and Consulting
3 Nature Aging | VOL 1 | July 2021 | p. 616–623
4 https://academic.oup.com/ije/article/50/Supplement_1/dyab168.034/6361231

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine